secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0001564590-23-007055
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA Biotechnology reports Q1 2023 net loss $4.1M; positive THIO-101 Phase 2 data and $5.75M offering
--------------------------------------------------------------------------------

- Cash $7.6M at March 31, 2023; net loss $4.1M for Q1 2023 vs $3.9M for Q1 2022.
- R&D expenses $2.2M, G&A expenses $2.0M for the quarter, both modestly higher YoY.
- Completed Part A safety lead-in of THIO-101 Phase 2 trial; first two patients alive ~10 and 9 months post treatment.
- THIO showed complete and durable responses in hepatocellular carcinoma in vivo models, potentiated with checkpoint inhibitor.
- Raised $5.75M gross from public offering of 2,555,500 shares at $2.25 per share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000156459023007055/0001564590-23-007055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000156459023007055/maia-8k_20230508.htm
  HTML page:      https://secwatch.observer/filing/0001564590-23-007055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer